Patents by Inventor Adam Robert MEZO

Adam Robert MEZO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered Antibody Compounds and Conjuates Thereof
    Publication number: 20200155702
    Abstract: Engineered antibody compounds and conjugates thereof, are provided, said antibody compounds and conjugates thereof are useful as agents for cancer immunotherapy.
    Type: Application
    Filed: June 14, 2018
    Publication date: May 21, 2020
    Inventors: Michael James Bacica, Yiqing Feng, Donmienne Doen Mun Leung, Matthew D. Linnik, Adam Robert Mezo, James Thomas Parker, Purva Vivek Trivedi, Francisco Alcides Valenzuela, Jianghuai Xu
  • Acylated insulin compound
    Patent number: 10597436
    Abstract: The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: March 24, 2020
    Assignee: Eli Lilly and Company
    Inventors: Wen Liu, Adam Robert Mezo, Francisco Alcides Valenzuela
  • ACYLATED INSULIN COMPOUND
    Publication number: 20190345215
    Abstract: The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.
    Type: Application
    Filed: August 1, 2019
    Publication date: November 14, 2019
    Inventors: Wen Liu, Adam Robert Mezo, Francisco Alcides Valenzuela
  • Acylated insulin compound
    Patent number: 10400021
    Abstract: The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: September 3, 2019
    Assignee: Eli Lilly and Company
    Inventors: Wen Liu, Adam Robert Mezo, Francisco Alcides Valenzuela
  • ACYLATED INSULIN COMPOUND
    Publication number: 20180340015
    Abstract: The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.
    Type: Application
    Filed: May 18, 2018
    Publication date: November 29, 2018
    Inventors: Wen Liu, Adam Robert Mezo, Francisco Alcides Valenzuela
  • Glucagon and GLP-1 co-agonist compounds
    Patent number: 9938335
    Abstract: The present invention provides glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: April 10, 2018
    Assignee: Eli Lilly and Company
    Inventors: Adam Robert Mezo, Yanyun Chen, Francisco Alcides Valenzuela, Hongchang Qu
  • GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS
    Publication number: 20160368960
    Abstract: The present invention provides glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
    Type: Application
    Filed: June 16, 2016
    Publication date: December 22, 2016
    Applicant: Eli Lilly and Company
    Inventors: Adam Robert MEZO, Yanyun CHEN, Francisco Alcides VALENZUELA, Hongchang QU